To explore the calcium-phosphorus metabolism and variation trend of immunoreactive parathyroid hormone (iPTH) of renal transplantation recipients after transplantation, and correct choice of treatment.

We retrospectively analyzed the clinical data of 179 recipients who got renal transplantation because of uremia between January 2012 to June 2014 in 309th Hospital of Chinese People′s Liberation Army. All the recipients suffered from secondary hyperparathyroidism (SHPT) and the renal function recoved to the estimated glomerular filtration rate (eGFR) >60 mL·min^-1·(1.73 m²)^-1 after transplantation. The average age of recipients was (34±6) years (18-61 years) and chronic kidney disease function were graded as 5T. Calcitriol (0.25 μg/d) was regularly used after transplantation to maintain normal serum levels of calcium and phosphate. Indexes like eGFR and serum calcium, phosphate and iPTH of recipients before and after transplantation were recorded. One-way analysis of variance for repeated measurement data was used to compare serum calcium, phosphate and iPTH of recipients before and 1 week, 1 month, 6 months, 12 months and 24 months after transplantation. Occurrence rate of hypophosphatemia and hypercalcemia, and distribution of iPTH were compared by Chi-square test.

Serum calcium of recipients after renal transplantation rised to stationary phase, meanwhile, serum phosphate fallen to stationary phase. Recipients had the highest occurrence rate of hypophosphatemia (9.5%, 17/179) and hypercalcemia (8.4%, 15/179) 6 months after transplantation. Serum iPTH declined significantly during 1 to 6 months after transplantation with no significant change later. For serum iPTH, only 24% (48/179) of recipients returned to more normal levels 24 months after transplantation.

Symptoms of SHPT of uremia patients were all alleviated, but most of them couldn′t return to normal level, which needed active and specific treatment after renal transplantation.